In draft guidance NICE has asked Janssen to provide more data on the effectiveness of their product, bortezomib (Velcade) as a treatment for some patients with newly diagnosed multiple myeloma. This appraisal is examining the use of bortezomib for treating multiple myeloma in combination with dexamethasone and thalidomide. The draft guidance has been issued for consultation and Janssen now has an opportunity to respond to the independent Appraisal Committee's considerations and requests. NICE has requested further evidence on the clinical and cost effectiveness of bortezomib in combination with dexamethasone compared with current standard treatment of newly diagnosed patients who are suitable for high dose chemotherapy with haematopoietic stem cell transplantation. Standard treatment in the UK is a combination of cyclophosphamide, thalidomide and dexamethasone. The draft guidance does not currently recommend bortezomib in combination with thalidomide and dexamethasone.

For more details, go to: http://www.nice.org.uk/newsroom/pressreleases/NICERequestsMoreDataBortezomibMultipleMyeloma.jsp